Literature DB >> 89531

Natural oestrogens for oral contraception.

J Serup, E Bostofte, S Larsen, J Westergaard, P E Lebech.   

Abstract

Mesh:

Substances:

Year:  1979        PMID: 89531     DOI: 10.1016/s0140-6736(79)91525-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study.

Authors:  Wolfgang Junge; Uwe Mellinger; Susanne Parke; Marco Serrani
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill.

Authors:  Maurizio Guida; Giuseppe Bifulco; Attilio Di Spiezio Sardo; Mariamaddalena Scala; Loredana Maria Sosa Fernandez; Carmine Nappi
Journal:  Int J Womens Health       Date:  2010-08-24

3.  Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel.

Authors:  Christine Klipping; Ingrid Duijkers; Susanne Parke; Uwe Mellinger; Marco Serrani; Wolfgang Junge
Journal:  Drugs R D       Date:  2011

4.  Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest.

Authors:  Johannes Bitzer; Susanne Parke; Thomas Roemer; Marco Serrani
Journal:  Int J Womens Health       Date:  2011-04-18

5.  Estradiol valerate and dienogest: a new approach to oral contraception.

Authors:  Jessica W Kiley; Lee P Shulman
Journal:  Int J Womens Health       Date:  2011-08-18

Review 6.  An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest.

Authors:  Franca Fruzzetti; Florence Trémollieres; Johannes Bitzer
Journal:  Gynecol Endocrinol       Date:  2012-04-02       Impact factor: 2.260

Review 7.  The pulmonary route as a way to drug repositioning in COVID-19 therapy.

Authors:  Michelle Alvares Sarcinelli; Thalita Martins da Silva; Andressa Daniele Artico Silva; Beatriz Ferreira de Carvalho Patricio; Flávia Costa Mendes de Paiva; Raissa Santos de Lima; Manuela Leal da Silva; Helvécio Vinícius Antunes Rocha
Journal:  J Drug Deliv Sci Technol       Date:  2021-02-24       Impact factor: 5.062

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.